Live
Endpoints NewsEuropean regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapyEndpoints NewsCSL sinks to nine-year low on revenue warning, $5B write-downPharmaVoiceWhen reliability becomes patient care in nuclear medicineBioPharma DivePrecision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapiesBioPharma DiveThe capacity crunch in biopharma is a location problemFierceBiotechQuantum firm hailed by Amgen tech leader as an ‘extraordinary platform’ plans IPOFierceBiotechMRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to RegistrationClinical OMICsEndometriosis May Increase Risk of Birth DefectseLifeRecombination shapes the diversification of the <i>wtf</i> meiotic driverseLifeAdult-neurogenesis allows for representational stability and flexibility in early olfactory systemeLifeCross-modal interaction of human alpha activity does not reflect inhibition of early sensory processing in a frequency-tagging study using EEG and MEGBoston ScientificBoston Scientific (BSX) Valuation Check After New Atrial Fibrillation And Stroke Prevention Data - simplywall.st
FierceBiotech Mar 26, 2026

OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline

OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline

Original
Body unavailable. Use the original source.